Immuron reports Travelan sales for January 2024

Immuron announced record sales of Travelan, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal tract. Sales of Travelan increased to AUD$2.1M YTD Jan 2024 compared to AUD$0.3M YTD Jan 2023. In the USA, sales of Travelan increased to AUD$0.6M YTD Jan 2024 vs AUD$0.3M YTD Jan 2023. Total U.S. citizen international visitor departures from the U.S. in November 2023 were 11% higher than in November 2022. In Canada, Immuron have recommenced Travelan sales in Canada through McKesson.